Drugs for muscles and brains

Neurotune AG
Wagistrasse 27a
8952 Schlieren-Zürich

Auf Karte anzeigen
Firmenbeschrieb
Neurotune, based in Schlieren (Zurich), Switzerland, was incorporated in January 2005 as a spin-off from Prionics AG. Neurotune develops small-molecular drugs to treat disorders of the human peripheral and central nervous system, as well as drugs to treat age-related muscle atrophy – Sarcopenia. The enormous economic potential of novel drugs for the treatment of central nervous system disorders lays ground for a successful development of the company. The scope of activities at Neurotune is drug development from preclinical R&D up to clinical Phase II out-licensing at the stage of clinical Phase II in-licensing of drug candidates Our core competences lie in biochemistry, neurological disorders of the central and peripheral nervous system medicinal chemistry on small molecular drugs

Gründungsjahr
2005
 
Rechtsform
Aktiengesellschaft (AG)
 
Anzahl Mitarbeiter
20
 


Eintrag erstellt: 05.10.2006, Letzte Änderung: 05.10.2006